NF‐κB activation is required for cisplatin‐induced apoptosis in head and neck squamous carcinoma cells

Authors:
  • JKJong Soo Kim
    Jong Soo Kim
  • JLJi Hye Lee
    Ji Hye Lee
  • WYWon Joon Yoon
    Won Joon Yoon
  • DLDong Seuk Lee
    Dong Seuk Lee
  • MKMyoung Seok Ko
    Myoung Seok Ko
  • BKByung Suk Kwon
    Byung Suk Kwon
  • DCDae Hwa Choi
    Dae Hwa Choi
  • HCHong Rae Cho
    Hong Rae Cho
  • BLByung Ju Lee
    Byung Ju Lee
  • DCDae Kyun Chung
    Dae Kyun Chung
  • HLHyeon Woo Lee
    Hyeon Woo Lee

Abstract
This study demonstrates a requirement for NF‐κB activation in cis‐diamminedichloroplatinum (cisplatin)‐induced apoptosis in human head and neck squamous cell carcinoma (HNSCC) cell lines. This conclusion was supported by the following observations: cisplatin induced IκBα degradation and NF‐κB‐dependent transcriptional activation prior to cell death; pyrrolidine dithiocarbamate (PDTC), a chemical inhibitor of NF‐κB activation, prevented apoptosis; lactacystin, an inhibitor of IκBα degradation, also prevented apoptosis; and finally, the expression of a super‐repressor mutant IκBα blocked apoptosis. The expression of tumor necrosis factor α (TNFα) was promoted by cisplatin treatment and was suppressed by PDTC treatment. In addition, a neutralizing antibody against TNFα protected cells from cisplatin‐induced apoptosis. These findings suggest that NF‐κB activation is required for cisplatin‐induced apoptosis and TNFα may play an important role in NF‐κB‐mediated apoptosis in cisplatin‐treated HNSCC cell lines.